Analyst Price Targets

AMC Stock Trades At 'Pre Meme Historical Multiple': Can Donut Holes, Salads And Billie Eilish Help Grow Revenue?
Affirm Holdings Selloff Is 'Baffling': Analysts Dive Into Financial Results
Robinhood Analysts 'Pleasantly Surprised' By Crypto Volume, Q2 Start: 'We See A Number Of Reasons To Be Positive'
Affirm Holdings Selloff Is 'Baffling': Analysts Dive Into Financial Results
Robinhood Analysts 'Pleasantly Surprised' By Crypto Volume, Q2 Start: 'We See A Number Of Reasons To Be Positive'
Airbnb Stock Plummets As JPMorgan Analyst Praises 'Solid Q1, Stable Q2, Acceleration In Q3'
Bumble Could 'Close Value Gap' To Tinder's Parent Company: Expert Predicts 45% Upside On Heels Of Q1 Earnings

Price Target Recent News

These Analysts Lower Their Forecasts On Revance Therapeutics After Q1 Results
Akamai Technologies Analysts Cut Their Forecasts After Weak Forecast
These Analysts Cut Their Forecasts On Allegro MicroSystems Following Q4 Results
ADMA Biologics Analysts Increase Their Forecasts After Upbeat Results
Celanese To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Friday
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields
Construction Partners Gears Up For Q2 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
DigitalOcean Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
SiTime Stock Skyrockets 30% After Analyst Upgrade
SITM up ~31% on Needham's upgrade to Buy with $130 PT. Beat & raise Q1 results with rebound in customer orders. Visibility improving for strong growth in 2024 and 2025.
Fox's Growth Prospects, Competitive Valuation Stand Out Against Disney, Paramount; Analyst Sees Momentum With Tubi, Sports
BofA Securities' Jessica Reif Ehrlich reiterates Buy rating on Fox Corp with $40 price target. Fiscal 2025 expected to accelerate earnings.
Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer
Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed, especially in pancreatic cancer, with stable disease maintained.
Arm Holdings Poised To Challenge Qualcomm, Intel, AMD In AI, Analysts Predict Growth In Chip Design
Arm Holdings stock drops after disappointing fiscal 2025 guidance, but analysts remain optimistic about AI and revenue growth.
EVgo's Q1 Performance Sparks Optimism, Analyst Upgrades Stock
Cantor Fitzgerald analyst upgrades EVgo to Overweight on solid sales growth and strategic moves. Q1 FY24 sales surge 118.2% YoY, surpassing estimates.
Shopify Profitability Remains A Concern, 5 Analysts Offer Commentary On Q1 Earnings
Shopify gross profit margins are expected to contract in the second quarter, one analyst says. The company's first-quarter beat was "modest."
Akamai Technologies Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Explore Benzinga's Financial Tools

Find Stocks Tailored to Your Trading Interests
Find Stocks Tailored to Your Trading Interests
Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Compare Benzinga's Favorite Stock Brokers

Claim Exclusive Offers

Compare Benzinga's Favorite Cryptocurrency Brokers

Claim Exclusive Offers